Target intelligence / Profile preview

Cyclic nucleotide-gated channel alpha-3 (CNGA3)

Target
CNGA3
Molecular classification
Ion channel, Cyclic nucleotide-gated channel
01

Overview

The Cyclic nucleotide-gated channel alpha-3 (CNGA3) is the pore-forming alpha subunit of the heterotetrameric cone photoreceptor CNG channel, assembling in a 3:1 stoichiometry with CNGB3 to form a functional complex essential for vertebrate phototransduction. In cone photoreceptors, it transduces light-induced decreases in cGMP levels into electrical signals by closing the channel, hyperpolarizing the membrane and reducing glutamate release. The channel conducts Na+ and Ca2+ ions in the dark when cGMP keeps it open, supporting steady depolarization. Structural features include an asymmetric selectivity filter with three glutamates, a hydrophobic cavity gate, and a putative lower gate formed by CNGB3 residues like R442, which influence ion permeation, Ca2+ block, and ligand gating. CNGA3 is regulated by phosphoinositides via N- and C-terminal domains, modulating cGMP/cAMP efficacy and adapting channel sensitivity. Pathogenic mutations in CNGA3, such as R410W or Q196L, disrupt channel function, causing achromatopsia—a congenital cone dystrophy with complete color blindness, photophobia, and nystagmus—and account for up to 95% of cases when combined with CNGB3 defects. No approved drugs directly target CNGA3, but its role in channelopathies suggests potential for gating modulators to address gain-of-function mutants that promote cone degeneration.

Other names
Cyclic nucleotide-gated channel subunit alpha-3Cone photoreceptor CNG channel alpha subunitCNG channel alpha-3
02

Biological functions

Signal transductionPhototransductionCation transport (Na+, Ca2+)Membrane depolarization
03

Disease associations

AchromatopsiaCone dystrophyChannelopathy
04

Safety considerations

Mutations cause constitutive channel activity leading to cone cell deathpotential for proteolysis if deglycosylatedspontaneously active mutants may accelerate cone degeneration

Beyond the preview

Go deeper on Cyclic nucleotide-gated channel alpha-3 (CNGA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic nucleotide-gated channel alpha-3 (CNGA3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call